<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Medical Journal of the Islamic Republic Of Iran</title>
<title_fa>مجله پزشکی جمهوری اسلامی ایران</title_fa>
<short_title>Med J Islam Repub Iran</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mjiri.iums.ac.ir</web_url>
<journal_hbi_system_id>2</journal_hbi_system_id>
<journal_hbi_system_user>journal2</journal_hbi_system_user>
<journal_id_issn>1016-1430</journal_id_issn>
<journal_id_issn_online>2251-6840</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.18869/mjiri</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1379</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2000</year>
	<month>11</month>
	<day>1</day>
</pubdate>
<volume>14</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>NEOADJUVANT CHEMOTHERAPY WITH VINCRISTINE AND CISPLATIN FOLLOWED BY RADICAL HYSTERECTOMY AND PELVIC LYMPH ADENECTOMY FOR FIGO STAGE IB BULKY CERVICAL CANCER</title>
	<subject_fa>Gynecology &amp; Obstetrics</subject_fa>
	<subject>Gynecology &amp; Obstetrics</subject>
	<content_type_fa>Original Research</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Twenty patients with bulky (&gt;4 cm size) FIGO stage IB cervical cancer were
treated with cisplatin 50 mg/m2 and vincristine 1 mg/m2, administered intravenously
at 10-day intervals for a total of 3 courses before radical hysterectomy. A
complete clinical response was noted in 1 patient (5%) and partial response in 5
(25%). Fourteen patients (70%) had stable disease. There was no grade 3 toxicity
noted. Of the 20 patients who received chemotherapy (ChT), 3 patients had parametrial
and para-aortic involvement in these cases, the operation was aborted and
radiation therapy given. The remaining 17 patients underwent radical hysterectomy
and pelvic lymphadenectomy 10-15 days following ChT. Five of these patients
(29.4%) had pelvic node metastases. Three patients had positive margins.
These 8 patients received postoperative radiotherapy. Twenty-four months later
15 patients were alive (87%) and 2 had died.
</abstract>
	<keyword_fa></keyword_fa>
	<keyword></keyword>
	<start_page>241</start_page>
	<end_page>243</end_page>
	<web_url>http://mjiri.iums.ac.ir/browse.php?a_code=A-10-298-314&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>N</first_name>
	<middle_name></middle_name>
	<last_name>BEHTASH</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006830</code>
	<orcid>20031947532846006830</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>From the Department of Gynecology-Oncology, Vali-E-Asr Hospital, Tehran University 0F Medical Sciences, Tehran, I.R. Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>M</first_name>
	<middle_name></middle_name>
	<last_name>MODARES</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006831</code>
	<orcid>20031947532846006831</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>F</first_name>
	<middle_name></middle_name>
	<last_name>GHAEM-MAGHAMI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006832</code>
	<orcid>20031947532846006832</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>A</first_name>
	<middle_name></middle_name>
	<last_name>MOUSAVI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006833</code>
	<orcid>20031947532846006833</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>K</first_name>
	<middle_name></middle_name>
	<last_name>SALEHI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006834</code>
	<orcid>20031947532846006834</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
